Polydex Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended October 31, 2022. For the third quarter, the company reported sales was USD 0.858089 million compared to USD 1.1 million a year ago. Net loss was USD 0.38293 million compared to USD 0.068676 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.02 a year ago.
For the nine months, sales was USD 3.11 million compared to USD 3.28 million a year ago. Net loss was USD 0.769548 million compared to USD 0.297118 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.22 compared to USD 0.09 a year ago.